JAIMIESS
Clinical safety rating
cautionComprehensive clinical and safety monograph for JAIMIESS (JAIMIESS).
Norepinephrine and dopamine reuptake inhibitor; also weakly inhibits serotonin reuptake. Enhances synaptic concentrations of norepinephrine and dopamine, particularly in prefrontal cortex.
| Metabolism | Hepatic via CYP2D6 to active metabolite hydroxybupropion; also CYP2B6 and CYP1A2 contribute. |
| Excretion | Primarily renal excretion as unchanged drug (approximately 70%) with the remainder as inactive metabolites; less than 10% excreted in feces. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in severe impairment). |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.5 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 70% (range 60-80%) with no significant food effect. |
| Onset of Action | Oral: 1-2 hours for peak plasma concentration; therapeutic effect typically seen within 2-4 weeks of continuous dosing. |
| Duration of Action | Duration of action is 24 hours with once-daily dosing; steady-state achieved after 5-7 days. |
| Molecular Weight | 467.53 |
| Action Class | Combined Oral Contraceptive (COC) |
100 mg orally once daily with food.
| Dosage form | TABLET |
| Renal impairment | In patients with GFR 30-89 mL/min, no dose adjustment required. For GFR 15-29 mL/min, reduce dose to 50 mg once daily. Not recommended if GFR <15 mL/min. |
| Liver impairment | For Child-Pugh Class A or B, no dose adjustment. For Child-Pugh Class C, reduce dose to 50 mg once daily. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment based on age alone; use caution due to potential age-related renal impairment. Monitor renal function. |
| 1st trimester | Contraindicated due to risk of fetal malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. |
| 2nd trimester | Contraindicated; may cause fetal growth restriction and oligohydramnios due to vascular effects. |
| 3rd trimester | Contraindicated; risk of neonatal complications such as renal dysfunction and thrombocytopenia. |
Clinical note
Comprehensive clinical and safety monograph for JAIMIESS (JAIMIESS).
| Placental transfer | Extensive placental transfer; maternal-fetal ratio approximately 0.85 in animal studies. |
| Breastfeeding | Excreted into breast milk in low amounts; however, due to long half-life and potential for serious adverse effects in infants (hypotension, hyperkalemia), use is not recommended. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: Risk of neural tube defects, cardiovascular anomalies, and oral clefts based on animal studies and limited human data. Second and third trimesters: Potential fetal growth restriction, oligohydramnios, and fetal/neonatal nephrotoxicity. Use only if benefit outweighs risk. |
| Fetal Monitoring | Serial fetal ultrasounds for growth assessment and amniotic fluid volume. Monitor maternal renal function, blood pressure, and electrocardiogram. Consider fetal echocardiography. |
| Fertility Effects | Animal studies show impaired fertility and embryotoxicity at therapeutic doses. Human data insufficient; likely reversible upon discontinuation. Men and women should use effective contraception during treatment and for 3 months after cessation. |
■ FDA Black Box Warning
May cause sudden death in children and adolescents with structural cardiac abnormalities or other serious heart problems; also associated with increased risk of suicidal thoughts and behaviors in children and adolescents with ADHD.
| Common Effects | Nausea, Breast tenderness, Headache, Breakthrough bleeding or spotting, Weight gain, Mood changes |
| Serious Effects | Venous thromboembolism (VTE), Arterial thromboembolism (e.g., stroke, myocardial infarction), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Worsening of migraine headaches |
PregnancyLactationHypersensitivity to active substance or any excipientSevere hepatic impairmentConcomitant use with strong CYP3A4 inhibitors
| Precautions | Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults; monitoring for emergence or worsening of depression, suicidal thoughts, and unusual changes in behavior; serious cardiovascular events; seizures (dose-dependent); psychosis; mania; narrow-angle glaucoma; hypertension; allergic reactions. |
| Food/Dietary | Grapefruit and grapefruit juice may increase estrogen exposure; avoid excessive consumption. High-fat meals can increase absorption of estradiol valerate; take with food if GI upset occurs. No other significant food interactions. |
| Clinical Pearls | JAIMIESS is a combination oral contraceptive containing estradiol valerate and dienogest. Use a four-phasic dosing regimen (E2V 3mg for 2 days, E2V 2mg/DNG 2mg for 5 days, E2V 2mg/DNG 3mg for 17 days, then placebo for 2 days) to mimic natural cycle. Monitor for thromboembolic events, especially in smokers over 35. Bleeding patterns may vary; breakthrough bleeding is common in first cycles. Consider backup contraception if doses missed. |
| Patient Advice | Take one tablet daily at the same time, in the order specified on the blister pack. · Use additional barrier contraception for the first 7 days of initial use. · Do not smoke while taking this medication, especially if over age 35. · Report any sudden severe headache, chest pain, leg pain, or vision changes. · If you miss a dose, follow the package instructions for missed pills; use backup contraception if needed. |
Loading safety data…